Allakos Inc logo

ALLK - Allakos Inc Share Price

$132.33 3.7  2.9%

Last Trade - 22/01/21

Large Cap
Market Cap £5.08bn
Enterprise Value £4.77bn
Revenue £n/a
Position in Universe 1112th / 6630
Unlock ALLK Revenue
Relative Strength (%)
1m -14.9%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -16.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, AllakosInc revenues was not reported. Net loss increased 80% to$109.2M. Higher net loss reflects Research and Development- Balancing increase of 65% to $69.2M (expense),Stock-based Compensation in SGA increase from $6.6M to$15.4M (expense), General and Administrative - Balancingincrease of 59% to $20.3M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ALLK Revenue Unlock ALLK Revenue

Net Income

ALLK Net Income Unlock ALLK Revenue

Normalised EPS

ALLK Normalised EPS Unlock ALLK Revenue

PE Ratio Range

ALLK PE Ratio Range Unlock ALLK Revenue

Dividend Yield Range

ALLK Dividend Yield Range Unlock ALLK Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ALLK EPS Forecasts Unlock ALLK Revenue
Profile Summary

Allakos, Inc. is a clinical-stage biotechnology company, which is engaged in developing antibodies that selectively target mast cells and eosinophils. The Company's antibodies target receptor molecules present on the surface of immune effector cells, which are involved in allergy, inflammation and tissue damage. Its lead program is AK002, which is an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. The Company's AK002 is used in the treatment of various diseases with abnormal proliferation of mast cells, including eosinophilic gastritis (EG), indolent systemic mastocytosis, urticaria and allergic conjunctivitis.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated March 9, 2012
Public Since July 19, 2018
No. of Shareholders: 17
No. of Employees: 114
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 52,503,346
Free Float (0.0%)
Eligible for
ALLK Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ALLK
Upcoming Events for ALLK
Tuesday 23rd February, 2021 Estimate
Q4 2020 Allakos Inc Earnings Release
Monday 10th May, 2021 Estimate
Q1 2021 Allakos Inc Earnings Release
Frequently Asked Questions for Allakos Inc
What is the Allakos Inc share price?

As of 22/01/21, shares in Allakos Inc are trading at $132.33, giving the company a market capitalisation of £5.08bn. This share price information is delayed by 15 minutes.

How has the Allakos Inc share price performed this year?

Shares in Allakos Inc are currently trading at $132.33 and the price has moved by 74.99% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Allakos Inc price has moved by 49.67% over the past year.

What are the analyst and broker recommendations for Allakos Inc?

Of the analysts with advisory recommendations for Allakos Inc, there are there are currently 4 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Allakos Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Allakos Inc next release its financial results?

Allakos Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Allakos Inc dividend yield?

Allakos Inc does not currently pay a dividend.

Does Allakos Inc pay a dividend?

Allakos Inc does not currently pay a dividend.

When does Allakos Inc next pay dividends?

Allakos Inc does not currently pay a dividend.

How do I buy Allakos Inc shares?

To buy shares in Allakos Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Allakos Inc?

Shares in Allakos Inc are currently trading at $132.33, giving the company a market capitalisation of £5.08bn.

Where are Allakos Inc shares listed? Where are Allakos Inc shares listed?

Here are the trading details for Allakos Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ALLK
What kind of share is Allakos Inc?

Based on an overall assessment of its quality, value and momentum, Allakos Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Allakos Inc share price forecast 2021?

Shares in Allakos Inc are currently priced at $132.33. At that level they are trading at 7.81% premium to the analyst consensus target price of 0.00.

Analysts covering Allakos Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.123 for the next financial year.

How can I tell whether the Allakos Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Allakos Inc. Over the past six months, the relative strength of its shares against the market has been 33.19%. At the current price of $132.33, shares in Allakos Inc are trading at 50.06% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Allakos Inc PE Ratio?

We were not able to find PE ratio data for Allakos Inc.

Who are the key directors of Allakos Inc?

Allakos Inc's management team is headed by:

John McKearn - IND
Robert Alexander - CEO
Adam Tomasi - PRE
Daniel Janney - NEC
Henrik Rasmussen - OTH
Steven James - IND
Robert Andreatta - IND
Mark Asbury - GCN
Leo Redmond - CFO
Natalie Holles - IND
Who are the major shareholders of Allakos Inc?

Here are the top five shareholders of Allakos Inc based on the size of their shareholding:

Alta Partners Venture Capital
Percentage owned: 16.23% (8.52m shares)
Capital World Investors Investment Advisor
Percentage owned: 11.04% (5.79m shares)
Capital Research Global Investors Investment Advisor
Percentage owned: 10.93% (5.74m shares)
RiverVest Venture Partners, LLC Venture Capital
Percentage owned: 9.4% (4.94m shares)
American Funds Growth Fund of America Mutual Fund
Percentage owned: 9.37% (4.92m shares)
Similar to ALLK
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.